• Pliant Therapeutics Inc PLRX.OQ reported a quarterly adjusted loss of 71 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -92 cents. The mean expectation of thirteen analysts for the quarter was for a loss of 70 cents per share. Wall Street expected results to range from $-1.09 to -48 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Pliant Therapeutics Inc's reported EPS for the quarter was a loss of 71 cents​.

• The company reported a quarterly loss of $43.3 million.

• Pliant Therapeutics Inc shares had risen by 45.7% this quarter and lost 87.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 8.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 11 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Pliant Therapeutics Inc is $3.00, about 44% above its last closing price of $1.68

This summary was machine generated from LSEG data August 8 at 04:07 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)